According to the Centers for Disease Control and Prevention (CDC), 38.6 million individuals, accounting for 11.6% of the entire United States population are affected by diabetes. Out of this, approximately 8.7 million are undiagnosed. Over 95% of people with diabetes have type 2 diabetes.
Moreover, diabetes is a major cause of blindness, kidney failure as well as heart attacks. hence, there has been significant emphasis on developing effective treatment alternatives to manage the condition effectively.
The Type 2 Diabetes Drug Pipeline Report by Expert Market Research gives comprehensive insights into type 2 diabetes drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on type 2 diabetes.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to type 2 diabetes are covered.
Type 2 diabetes is a chronic condition which affects the glucose synthesis in the body, resulting in high blood sugar levels. It is also known as adult-onset diabetes and is more common than type 1 diabetes. it leads to excessive blood sugar levels in the blood and may cause circulatory, nervous and immune system disorders as well.
Type 2 diabetes is more common in adults. It is caused by insulin resistance and the inability of the pancreas to produce enough insulin to manage blood sugar levels. Common symptoms include increased thirst, frequent urination urge, surge in hunger levels, blurred vision, unintended weight loss, tingling sensation or numbing in feet or hands. Having high-fat accumulation around the abdomen or hips, and obesity are some of the major risk factors for type 2 diabetes. As a result, lifestyle modifications such as frequent exercise, and dietary changes are mostly advised treatments.
Type 2 diabetes drugs can be both oral as well as injectable. Oral drugs include several drug classes like Biguanides (metformin), Sulfonylureas (Glipizide, Glyburide, Glimepiride) and others. GLP-1 receptor agonists (a part of injectable medications) are gaining significant popularity in the market. Several type 2 diabetes drugs in the pipeline are being developed by several prominent healthcare and pharmaceutical companies. There is an influx of investment to combat the rising fatalities associated with type 2 diabetes across the globe.
This section of the report covers the analysis of type 2 diabetes drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials conducted, with over 1,514 drugs in the pipeline.
The drug class categories covered under type 2 diabetes pipeline analysis include Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones (TZDs), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, and Alpha-Glucosidase Inhibitors. Glucagon-like Peptide-1 (GLP-1) receptor agonists stimulate insulin release and prevent glucagon release, resulting in satiated feeling. Drugs belonging to this drug class are gaining popularity. Common examples include Liraglutide and Semaglutide among others.
The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
The EMR report for the type 2 diabetes drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in type 2 diabetes clinical trials:
Afrezza®
Afrezza, designed for type 2 diabetes treatment, is being evaluated in the INHALE-1 trial. The study evaluates its efficacy against insulin analog injections. The drug is particularly being investigated for pediatric patients. Sponsored by Mannkind Corporation, INHALE-1 is a 26-week Primary Treatment Phase, randomized clinical trial.
XW-004
Sciwind Biosciences (Sciwind) is developing XW-004 for type 2 diabetes, obesity as well as nonalcoholic steatohepatitis (NASH). It is a glucagon-like peptide 1 receptor (GLP1R) oral drug developed using polypeptide or recombinant protein preparation platform technology.
Investigational Tirzepatide (LY3298176)
Eli Lilly and Company’s Tirzepatide is under investigation for its efficacy and safety in obese type 2 diabetes participants that are on metformin. Currently in phase 3 of an interventional study, enrolling over 13,000 people, this trial is likely to be completed by June 2025.
The Type 2 Diabetes Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for type 2 diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
USD 1,999
tax inclusive*
Single User License
One User
USD 2,499
tax inclusive*
Five User License
Five Users
USD 3,499
tax inclusive*
Corporate License
Unlimited Users
USD 4,499
tax inclusive*
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-120-433-0800
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
